Several randomised, placebo-controlled trials have demonstrated that PDE4 inhibitors, such as cilomilast and roflumilast, improve lung function, decrease the risk of exacerbation [25,26], and even reduce the frequency of exacerbations requiring systemic corticosteroid therapy in patients with severe COPD [26]. Here, PDE4A is linked to chronic obstructive pulmonary disease.